The SME has developed an innovative solution that meets today’s business need in the diagnostic market. Instrument is a pocket-size molecular biology laboratory. The test material can be, e.g., whole blood, swab, cerebrospinal fluid. The proprietary, patented technology of controlling the processes occurring on the microfluidic card using photon energy is highly efficient. This enables the isothermal amplification and detection of pathogen-specific fragments of genetic material or mutations in a record time - less than 15 minutes and with an efficiency of 99%. Moreover, in the combination with the nucleic acid extraction and concentration procedure, the systems demonstrate a significant reduction in the DNA or RNA (ribonucleic acid) detection limit, thereby resulting in the recognition of infection at an earlier stage. The research may be subject to: bacteria, viruses, fungi, genetic mutations.
The Polish company will be one of the few producers of mobile molecular analyzers in the world as well as the only one on the European market. The company offers the first technology in the world based on the gold standards of the molecular diagnostics. This is a breakthrough solution, which does not require the support of experienced diagnostics or modern laboratories. Thanks to offered by SME solutions, the use of molecular technologies will be simpler than ever: it is enough to apply biological material to the reaction card and run the analyzer. First products intended for respiratory tract infections will be available in 2021 after gaining regulatory approval in EU.
In order to increase the performance of international coopearation the company is looking for the distribution services agreement. Moreover the SME is interested in healthcare industry for a subcontracting agreement. The subcontracting services are offered to companies that are not able to produce of mobile molecular analyzers and search for companies with skilled personnel and know-how or need the subcontractor for orders in diagnostic sphere.